Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

PFE Balance Sheet

Assets, liabilities, and equity analysis

PFE Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/29/2026
12/31/2025
09/28/2025
06/29/2025
03/30/2025
03/29/2025
12/31/2024
09/29/2024
Total Current Assets
42.822B42.822B42.898B46.924B43.703B45.861B50.358B43.223B
1.703B1.703B1.142B1.343B1.638B1.430B1.043B1.092B
Short-Term Investments
11.372B11.372B12.454B13.641B11.611B15.886B19.434B8.860B
Cash & Short-Term Investments
13.075B13.075B13.596B14.984B13.249B17.316B20.477B9.952B
12.585B12.585B11.874B14.260B12.078B14.745B14.777B17.694B
10.667B10.667B10.654B11.468B11.669B0.0010.852B10.851B11.721B
Total Assets
207.618B207.618B208.160B208.731B206.095B208.028B213.396B219.476B
19.402B19.402B21.530B18.880B18.776B18.347B18.393B18.541B
71.409B71.409B71.264B69.101B68.997B68.444B68.527B68.570B
Intangible Assets
52.559B52.559B53.731B51.324B52.702B53.974B55.412B59.986B
Long-Term Investments
1.626B1.626B1.737B2.137B224.000M2.014B2.227B10.762B
Total Current Liabilities
34.348B34.348B36.984B36.596B37.726B36.452B42.995B43.211B
4.506B4.506B5.240B5.024B5.166B5.240B5.633B5.314B
3.890B3.890B3.484B4.303B4.295B4.471B6.946B9.699B
Total Liabilities
117.214B117.214B121.385B115.635B117.083B117.391B124.899B126.918B
60.565B60.565B61.641B57.409B57.502B56.820B56.703B56.918B
64.455B64.455B67.416B61.712B61.797B61.291B63.649B66.617B
Net Debt (Cash)
62.752B62.752B66.274B60.369B60.159B59.861B62.606B65.525B
Total Shareholders' Equity
90.101B90.101B86.476B92.801B88.695B90.338B88.203B92.286B
Common Stock
482.000M482.000M481.000M481.000M481.000M481.000M480.000M480.000M
117.238B117.238B114.610B121.150B117.609B119.590B116.725B121.059B
1.251.251.161.281.161.261.171.00
0.720.720.780.660.700.680.720.72

PFE Annual Balance Sheet (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Total Current Assets
42.898B50.358B43.333B51.259B59.693B35.067B32.803B49.926B
1.142B1.043B2.853B416.000M1.944B1.786B1.121B1.139B
Short-Term Investments
12.454B19.434B9.837B22.316B29.125B10.437B8.525B17.694B
Cash & Short-Term Investments
13.596B20.477B12.690B22.732B31.069B12.223B9.646B18.833B
11.874B14.777B15.544B14.529B15.745B11.177B9.508B11.399B
10.654B10.851B10.189B8.981B9.059B8.046B7.068B7.508B
Total Assets
208.160B213.396B226.501B197.206B181.477B154.229B167.488B159.422B
21.530B18.393B18.940B16.274B14.882B13.745B12.969B13.385B
71.264B68.527B67.783B51.375B49.208B49.556B48.202B53.411B
Intangible Assets
53.731B55.412B64.900B43.370B25.146B28.336B33.936B35.211B
Long-Term Investments
1.737B2.227B15.368B15.069B21.526B20.262B20.147B2.767B
Total Current Liabilities
36.984B42.995B47.794B42.138B42.671B25.920B37.304B31.858B
5.240B5.633B6.710B6.809B5.578B4.283B3.887B4.674B
3.484B6.946B10.346B2.934B2.241B2.703B16.190B8.836B
Total Liabilities
121.385B124.899B137.213B101.289B104.014B90.756B104.147B95.664B
61.641B57.405B60.499B31.925B34.757B35.571B34.650B32.909B
67.416B66.993B70.845B34.859B36.998B38.274B50.840B41.745B
Net Debt (Cash)
66.274B65.950B67.992B34.443B35.054B36.488B49.719B40.606B
Total Shareholders' Equity
86.476B88.203B89.014B95.661B77.201B63.238B63.143B63.407B
Common Stock
481.000M480.000M478.000M476.000M473.000M470.000M468.000M467.000M
114.610B116.725B118.353B125.656B103.394B96.770B97.670B89.554B
1.161.170.911.221.401.350.881.57
0.780.760.800.360.480.610.810.66

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla